SERLENQA Trademark

Trademark Overview

On Monday, April 19, 2010, a trademark application was filed for SERLENQA with the United States Patent and Trademark Office. The USPTO has given the SERLENQA trademark a serial number of 85017434. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 24, 2014. This trademark is owned by Glaxo Group Limited. The SERLENQA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; and for vaccines
serlenqa

General Information

Serial Number85017434
Word MarkSERLENQA
Filing DateMonday, April 19, 2010
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 24, 2014
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 21, 2010

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; and for vaccines
Translation of Words in MarkThe word " SERLENQA" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 23, 2010
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGreenford, Middlesex UB60NN
GB

Trademark Events

Event DateEvent Description
Monday, March 24, 2014ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, March 24, 2014ABANDONMENT - NO USE STATEMENT FILED
Thursday, August 15, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 14, 2013EXTENSION 5 GRANTED
Wednesday, August 7, 2013EXTENSION 5 FILED
Wednesday, August 7, 2013TEAS EXTENSION RECEIVED
Monday, March 25, 2013APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, March 25, 2013TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, March 15, 2013ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, March 15, 2013TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, February 2, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 1, 2013EXTENSION 4 GRANTED
Wednesday, January 30, 2013EXTENSION 4 FILED
Wednesday, January 30, 2013TEAS EXTENSION RECEIVED
Tuesday, August 7, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 6, 2012EXTENSION 3 GRANTED
Thursday, August 2, 2012EXTENSION 3 FILED
Thursday, August 2, 2012TEAS EXTENSION RECEIVED
Thursday, January 26, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 25, 2012EXTENSION 2 GRANTED
Monday, January 23, 2012EXTENSION 2 FILED
Monday, January 23, 2012TEAS EXTENSION RECEIVED
Saturday, August 13, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 12, 2011EXTENSION 1 GRANTED
Wednesday, July 27, 2011EXTENSION 1 FILED
Friday, August 12, 2011CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, July 27, 2011TEAS EXTENSION RECEIVED
Tuesday, February 15, 2011NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 21, 2010OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 21, 2010PUBLISHED FOR OPPOSITION
Friday, November 12, 2010LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, November 10, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 9, 2010TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 9, 2010CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 5, 2010ASSIGNED TO LIE
Tuesday, October 19, 2010TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 2, 2010NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 2, 2010NON-FINAL ACTION E-MAILED
Monday, August 2, 2010NON-FINAL ACTION WRITTEN
Tuesday, July 27, 2010ASSIGNED TO EXAMINER
Thursday, May 13, 2010TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, April 23, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 22, 2010NEW APPLICATION ENTERED IN TRAM

Related Keywords

serlenqa pharmaceutical treatment substances disorders preparations diseases hormonal neurological gastrointestinal ophthalmic